Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins | Zendy

Kausik K. Ray | Zendy; Robert M. Stoekenbroek | Zendy; David Kallend | Zendy; Lawrence A. Leiter | Zendy; Ulf Landmesser | Zendy; R. Scott Wright | Zendy; Peter Wijngaard | Zendy; John J.P. Kastelein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

Author(s) -

Kausik K. Ray,

Robert M. Stoekenbroek,

David Kallend,

Lawrence A. Leiter,

Ulf Landmesser,

R. Scott Wright,

Peter Wijngaard,

John J.P. Kastelein

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.034710

Subject(s) - pcsk9 , medicine , kexin , proprotein convertase , ldl receptor , ldl cholesterol , cholesterol , pharmacology , lipoprotein

The ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) demonstrated that inclisiran, an siRNA therapeutic that targets protease proprotein convertase subtilisin/kexin type 9 mRNA within hepatocytes, produces significant low-density lipoprotein cholesterol reduction. The effects of inclisiran on other lipids are less well described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research